Terumo Corporation · TSE:4543

Terumo — Q1 2027 Earnings Presentation

23 slides from Terumo's earnings presentation, Aug 7, 2026

  1. Slide 1: Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (FY2026)

    Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (FY2026) Jin Hagimoto Chief Financial Officer Terumo Corporation Aug. 7, 2026

  2. Slide 2: Forward-Looking Statements and Use of Document

    Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performanc

  3. Slide 3: Highlights

    Highlights Revenue Achieved highest ever results for the quarter Continued strong sales, driven by the Americas, with 9% growth excluding FX impact Profit Operating profit, adjusted operating profit, and profit for the period all reached record highs for the quarter Significant profit growth achieve

  4. Slide 4: P&L, FCF

    P&L, FCF Revenue: Continued strong demand for TIS and Global Blood Solutions, supported by favorable FX impact Operating profit: Increased significantly due to higher sales, a tariff refund, and one-time income Change 100M JPY FY25 Q1 FY26 Q1 Change excluding FX impact Revenue 2,600 3,118 20% 9% Gro

  5. Slide 5: OP Variance Analysis: Growth due to strong sales and a tariff refund

    OP Variance Analysis: Growth due to strong sales and a tariff refund (100M JPY) 895 G/P increment by sales increase: TIS and GBS led the overall growth, OT 116 43 796 growth also contributed 128 -67 Gross margin/Price: -16 FX Significant profit increase due to pricing Gross SG&A R&D Margin/ measures

  6. Slide 6: C&V: TIS led growth, TN and TCV also performed well

    C&V: TIS led growth, TN and TCV also performed well (C&V: Cardiac & Vascular) (100M JPY) Q1 Q1 Comments YoY ( ) FX Neutral 1,881 TIS : Continued strong performance across all product +210 Terumo areas, primarily in North America. Asia also 1,567 1,578 Interventional achieved double-digit growth excl

  7. Slide 7: TMCS: HCS and PS drove revenue and profit growth

    TMCS: HCS and PS drove revenue and profit growth (TMCS: Medical Care Solutions) (100M JPY) Q1 Q1 Comments YoY ( ) FX Neutral 566 HCS : In Japan, revenue increased due to pricing +36 518 504 Hospital Care revisions and strong sales of core product lines. Solutions Overseas revenue was also supported

  8. Slide 8: TBCT: Strong global demand for blood collection products; Rika also contributed

    TBCT: Strong global demand for blood collection products; Rika also contributed (TBCT: Blood and Cell Technologies) (100M JPY) Q1 Q1 Comments YoY ( ) FX Neutral 608 516 GBS : Strong sales of blood collection products in US +69 497 Global Blood and Europe; Rika (source plasma collection Solutions sys

  9. Slide 9: OT: Rapid Revenue Growth Driven by Expanding Liver Transplant Market

    OT: Rapid Revenue Growth Driven by Expanding Liver Transplant Market (OT: Terumo Organ Technologies) Quarterly Revenue Trend Comments (100M JPY) Revenue: 6.2 B JPY +39% growth year-on-year • Continued revenue growth driven by rising liver transplant volumes and customer base expansion Adjusted Opera

  10. Slide 10: Revenue by Region: Growth led by Americas, Europe, and Asia

    Revenue by Region: Growth led by Americas, Europe, and Asia FY26 Q1 Revenue (100M JPY) Comments FY26 Q1 YoY Change Regional ( ) FX Neutral breakdown Strong demand continued across all companies, FY24 959 led by TIS, TCV, and HCS. OT also contributed Americas FY25 1,005 26% (12%) significantly FY26 1

  11. Slide 11: Revision of FY26 Guidance

    Revision of FY26 Guidance ©TERUMO CORPORATION 11

  12. Slide 12: Revision of FY26 Guidance

    Revision of FY26 Guidance Upward revision to adjusted operating profit, operating profit, and profit for the year (Revenue unchanged) Assumptions • US tariff refund: Reflects 13.0 billion JPY paid in the previous fiscal year • Other Income: Reflects 20.0 billion JPY of settlement proceeds (classifie

  13. Slide 13: Revision of FY26 Guidance by Company

    Revision of FY26 Guidance by Company Revenue Adjusted Operating Profit Amount FY25 FY26 FY26 FY25 FY26 FY26 FY26 (100M JPY) Previous Revised Revision Change Previous Revised Revision Change Revised Results Results Guidance Guidance Guidance (C)-(B) (C)/(A) Guidance Guidance (C)-(B) (C)/(A) (A) (A) A

  14. Slide 14: Reference

    Reference ©TERUMO CORPORATION 14

  15. Slide 15: P&L (QoQ)

    P&L (QoQ) (100M JPY) FY25 Q1 Q2 Q3 Q4 FY26 Q1 (Apr-Jun) (Jun-Sep) (Oct-Dec) (Jan-Mar) (Apr-Jun) Revenue 2,600 2,750 2,966 3,003 3,118 Gross Profit 1,455 (56.0%) 1,470 (53.5%) 1,532 (51.6%) 1,490 (49.6%) 1,785 (57.3%) SG&A Expenses 755 (29.1%) 808 (29.4%) 869 (29.3%) 898 (29.9%) 907 (29.1%) R&D Expen

  16. Slide 16: SG&A (QoQ)

    SG&A (QoQ) (100M JPY) FY25 Q1 Q2 Q3 Q4 FY26 Q1 (Apr-Jun) (Jul-Sep) (Oct-Dec) (Jan-Mar) (Apr-Jun) Salaries & Wages 406 421 447 468 502 Sales Promotion 55 53 61 62 61 Logistics Costs 57 59 58 58 62 Depreciation and Amortization 68 70 76 76 73 Others 169 205 228 233 210 SG&A Expenses Total 755 808 869

  17. Slide 17: SG&A (YoY)

    SG&A (YoY) (100M JPY) YoY% FY25 Q1 FY26 Q1 YoY% Excluding FX impact Salaries & Wages 406 502 24% 13% Sales Promotion 55 61 11% 3% Logistics Costs 57 62 8% 0% Depreciation and Amortization 68 73 6% -2% Others 169 210 24% 15% SG&A Expenses 755 907 20% 10% (%) (29.1%) (29.1%) R&D Expenses 164 190 15% 9

  18. Slide 18: Adjusted Operating Profit: Adjustments

    Adjusted Operating Profit: Adjustments (100M JPY) FY25 Q1 FY26 Q1 Adjusted Operating Profit 591 796 Adjustment 1. Amortization of -51 -72 acquired intangible assets Adjustment 2. Non-recurring profit or loss 19 171 Operating Profit 559 895 Adjustment 2. Non-recurring profit or loss FY25 Q1 FY26 Q1 <

  19. Slide 19: CAPEX, Depreciation and Amortization, R&D Expenses

    CAPEX, Depreciation and Amortization, R&D Expenses (100M JPY) FY26 FY23 FY24 FY25 FY26Q1 Guidance CAPEX 784 825 971 168 920 Depreciation 702 781 867 251 990 Amortization of acquired intangible assets 200 210 242 72 290 Others 502 571 625 179 700 CAPEX = Construction in progress record basis, lease d

  20. Slide 20: Free Cash Flow

    Free Cash Flow (100M JPY) 272 903 -240 Depreciation Income CAPEX 745 and taxes, etc. -135 -55 amortization Working Others capital Other -188 462 operating -95 CF FY26Q1 YTD Operating CF FCF Profit before tax YoY +351 +60 -88 +54 +42 +418 +15 -78 +355 ©TERUMO CORPORATION 20

  21. Slide 21: Cash Flow

    Cash Flow Operating CF Investing and financing CF (100M JPY) +745 -404 272 903 -240 Depreciation 1,780 and Income -190 amortization taxes. -188 3,146 Working -219 etc. CAPEX -77 capital, etc. 2,805 Dividends Others Profit before tax -1,700 Issuance of Repayment CP and of short-term borrowings borrow

  22. Slide 22: Foreign Exchange Sensitivity

    Foreign Exchange Sensitivity Annual impact of 1 JPY depreciation (Flow) (100M JPY) USD EUR CNY Revenue 33 13 46 +20% Adjusted Operating Profit (+8%) 5 7 24 1,349 Impact of 1 JPY depreciation (Stock) (100M JPY) 1,198 2,049 USD EUR CNY 38% Adjusted Operating Profit (+13%) -3.0 -1.0 -2.5 ©TERUMO CORPOR

  23. Slide 23: ~“TERUMO

    ~“TERUMO

Terumo — Q1 2027 Earnings Presentation on 6ix